INGRAM-MICRO-CLOUD
12.11.2021 09:02:10 CET | Business Wire | Press release
Ingram Micro Cloud today announced that it is now distributing a full range of Amazon Web Services, Inc. (AWS) products and services to its reseller network in Hungary and Poland. The move bolsters the global offering of Ingram Micro’s Cloud Marketplace, one of the world’s most comprehensive and broadly adopted set of cloud solutions.
Ingram Micro Cloud, an AWS Advanced Consulting Partner and AWS Distributor, announced its global Strategic Collaboration Agreement (SCA) with AWS in March this year. One of the central objectives of the agreement between the business leaders is extending the global reach and footprint of AWS and its partners. As part of this global expansion, Ingram Micro Cloud is now delivering a complete portfolio of AWS solutions to resellers in Hungary and Poland, in addition to its recent launches in France, Mexico, Australia, and New Zealand, which were part of a series of authorizations in 2021. As a result of the SCA with AWS, Ingram Micro expects its large network of partners to see new opportunities to meet customer needs and expand their infrastructure as a service (IaaS) business.
"The distribution alliance between Ingram Micro Cloud and AWS in our region is a great strategic milestone for us,” said Attila Virágh, Managing Director at Ingram Micro Hungary. “Teaming further with AWS brings tremendous opportunity and additional business value to our channel partners within the cloud ecosystem by helping them execute at scale, and quickly meet the business needs of their customers.”
“I’m happy to see AWS joining our marketplace offering in Central and Eastern Europe. I am confident this relationship will significantly contribute to the acceleration of as-a-service models and customers’ cloud migration,” said Jacek Jedraszka, Managing Director at Ingram Micro Poland.
AWS and Ingram Micro Cloud are working together to bolster Ingram Micro Cloud’s current skills and offerings, as well as develop new resources to support channel partners in managing end customers. Ingram Micro Cloud currently provides an AWS Cloud Center of Excellence (CCoE) team with 200+ AWS Certifications, AWS Professional Services, AWS Managed Services, AWS Well-Architected Services, AWS Operations and Billing Services, and more.
Ingram Micro Cloud also covers a wide range of partner enablement and support initiatives to help AWS Partners build an AWS practice through its partner programs, which provide end-to-end engagement models for Ingram Micro Cloud to enable systems integrators (SIs) and independent software vendors (ISVs) in their journey on the cloud.
“We are pleased to differentiate our broad portfolio of cloud services with the addition of AWS on our Cloud Marketplace,” said Nora Papp, Head of Cloud for Central and Eastern Europe at Ingram Micro. “Through this important expansion of pioneering solutions and services, Ingram Micro Cloud is offering our reseller partners the seamless capability to build a successful AWS practice and deliver greater value to their customers.”
Further information about Ingram Micro Cloud’s AWS offerings can be found here .
About Ingram Micro Cloud
Ingram Micro Cloud brings together innovators and problem solvers to help the world accomplish more. It facilitates and manages the cloud’s complex digital value chain—all powered by CloudBlue technology. Ingram Micro Cloud operates in 76 countries with over 55,000 reseller partners, and its Cloud Marketplace serves 17.2 million seats, offering more than 120 cloud solutions. With unmatched global reach, easy access to automated go-to-market and integration tools, deep technical expertise, and a curated selection of scalable SaaS and IaaS solutions, Ingram Micro Cloud helps vendors, resellers and managed service providers by offering More as a Service. Detailed information is available at www.IngramMicroCloud.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom